- Exhibit & Support
- Hotel & Travel
Only one-third of individuals who are eligible for migraine preventive regimens actually receive them, and over 75% of these individuals become noncompliant due to adverse effects and lack of efficacy. Recently, calcitonin gene-related peptide (CGRP) antagonists were approved for preventive treatment against migraines, and they have been proven to be more effective and safer than previous therapies. Pharmacists have an important role in educating patients on medication and proper administration along with encouraging patient compliance in order for the patient to receive optimal therapeutic effects.
Speakers: Nikki Hahn, PharmD, BCACP, Kaiser Permanente of Colorado; Paul Mathew, MD, FAAN, FAHS, Harvard Medical School
Register today at https://www.pharmacytimes.org/go/migraine2019 .
At the completion of this activity, participants will be able to: